Polivy (polatuzumab vedotin-piiq)

P1, N=30, Recruiting, National Cancer Institute (NCI) | Suspended --> Recruiting

P2, N=5, Terminated, UNC Lineberger Comprehensive Cancer Center | Trial completion date: Nov 2026 --> Oct 2025 | Active, not recruiting --> Terminated; Funding

P1/2, N=20, Recruiting, New York Medical College | Trial completion date: Aug 2025 --> Aug 2027 | Trial primary completion date: Aug 2024 --> Aug 2026

P2, N=125, Active, not recruiting, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Trial completion date: Sep 2028 --> Feb 2028

P2, N=30, Not yet recruiting, Ruijin Hospital

Post-CAR-T salvage therapy consisted of heterogeneous regimens, most commonly polatuzumab-bendamustine-rituximab and CD20 × CD3 bispecific antibody monotherapy. Response rates and short-term survival varied across approaches, with bispecific antibody monotherapy having the highest ORR (65%) and favorable 1-year outcomes (OS 56%; EFS 43%). In this contemporary multicenter cohort, salvage therapy after CAR-T failure achieved objective but often short-lived responses, with outcomes driven by relapse timing after CAR-T infusion rather than the line of prior CAR-T therapy, supporting individualized treatment selection in this high-risk setting.

P2, N=30, Not yet recruiting, Brown University

P2, N=35, Recruiting, The First Affiliated Hospital of Soochow University

P3, N=1130, Active, not recruiting, Hoffmann-La Roche | Trial primary completion date: Dec 2027 --> Oct 2027

To achieve this, anthracycline-based chemotherapy in combination with rituximab is typically administered as initial therapy...In patients with the activated B-cell subtype of DLBCL, polatuzumab vedotin is commonly included in the combination...In patients ineligible for cellular therapy, or those who progress after CAR T-cell treatment, management is palliative and includes administration of bispecific antibodies or antibody drug conjugate combinations. To further improve the outcome of DLBCL patients, incorporation of cellular and bispecific therapies into front-line treatment is currently being tested.

Conventional platinum-based or gemcitabine- and bendamustine-containing regimens retain a role for short-term disease control but offer limited durability. In contrast, novel antibody-based therapies, including polatuzumab-containing combinations, loncastuximab tesirine, and tafasitamab plus lenalidomide, have expanded treatment options with improved tolerability. Most notably, CD20 × CD3 bispecific antibodies represent a major therapeutic advance, providing off-the-shelf immune engagement with predominantly outpatient administration. From a practical perspective, early identification of reversible barriers to CAR T-cell therapy and timely use of bispecific antibodies or other antibody-based regimens are critical to achieve rapid disease control, preserve organ function, and, when feasible, restore eligibility for cellular therapy.

P2, N=41, Recruiting, Jennifer Crombie, MD | Active, not recruiting --> Recruiting